Cumberland Pharmaceuticals (CPIX) Set to Announce Quarterly Earnings on Thursday

Cumberland Pharmaceuticals (NASDAQ:CPIX) is scheduled to be announcing its earnings results after the market closes on Thursday, November 7th. Investors that wish to listen to the company’s conference call can do so using this link.

Cumberland Pharmaceuticals Stock Up 0.9 %

CPIX traded up $0.01 on Tuesday, hitting $1.15. The company had a trading volume of 42,090 shares, compared to its average volume of 12,976. The company has a debt-to-equity ratio of 0.62, a current ratio of 1.44 and a quick ratio of 1.26. Cumberland Pharmaceuticals has a 52-week low of $1.07 and a 52-week high of $2.36. The stock has a fifty day simple moving average of $1.26 and a 200-day simple moving average of $1.42. The firm has a market capitalization of $16.22 million, a P/E ratio of -1.58 and a beta of 0.22.

Analyst Ratings Changes

Separately, StockNews.com began coverage on shares of Cumberland Pharmaceuticals in a report on Saturday. They set a “hold” rating for the company.

About Cumberland Pharmaceuticals

Cumberland Pharmaceuticals Inc, a specialty pharmaceutical company, focuses on the acquisition, development, and commercialization of prescription products for hospital acute care, gastroenterology, and oncology in the United States and internationally. The company offers Acetadote, an injection for the treatment of acetaminophen poisoning; Caldolor, an injection for the treatment of pain and fever; Kristalose, a prescription laxative oral solution for the treatment of constipation; Omeclamox-Pak for the treatment of Helicobacter pylori infection and duodenal ulcer disease; Vaprisol, an injection for treating euvolemic and hypervolemic hyponatremia; Sancuso, an injection for the treatment of chemotherapy treatment; and Vibativ, an injection for the treatment of certain serious bacterial infections, including hospital-acquired and ventilator-associated bacterial pneumonia, as well as complicated skin and skin structure infections.